Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small nuclear ribonucleoprotein polypeptide B2 (SNRPB2) is a protein encoded by the SNRPB2 gene in humans. It is a core component of the U2 small nuclear ribonucleoprotein (U2 snRNP) complex, which is part of the spliceosome—the molecular machinery responsible for the removal of introns from pre-mRNA during mRNA splicing. SNRPB2 specifically binds to stem loop IV of U2 snRNA and is required for proper spliceosome function. Autoantibodies against SNRPB2 are frequently found in patients with systemic lupus erythematosus, highlighting its immunological relevance. Mutations or dysregulation of SNRPB2 are associated with diseases such as spinal muscular atrophy[1][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small nuclear ribonucleoprotein polypeptide B2 (SNRPB2).